Pluronic F127 micelles improve the stability and enhance the anticancer stem cell efficacy of citral in breast cancer

Nanomedicine (Lond). 2021 Jul;16(17):1471-1485. doi: 10.2217/nnm-2021-0013. Epub 2021 Jun 23.

Abstract

Aim: Improving the stability and anti-cancer stem cell (CSC) activity of citral, a natural ALDH1A inhibitor. Materials & methods: Citral-loaded micelles (CLM) were obtained using Pluronic® F127 and its efficacy tested on the growth of four breast cancer cell lines. The impact of the CLM on the growth and functional hallmarks of breast CSCs were also evaluated using mammosphere and CSC reporter cell lines. Results: CLM improved the stability and growth inhibitory effects of citral. Importantly, CLM fully blocking the stemness features of CSCs (self-renewal, differentiation and migration) and in combination with paclitaxel CLM sensitized breast cancer cells to the chemotherapy. Conclusion: Targeting CSCs with CLM could improve the treatment of advanced breast cancer in combination with the standard chemotherapy.

Keywords: F127; Pluronic®; breast cancer; cancer stem cells; citral; polymeric micelles.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acyclic Monoterpenes
  • Breast Neoplasms* / drug therapy
  • Cell Line, Tumor
  • Female
  • Humans
  • Micelles*
  • Neoplastic Stem Cells
  • Poloxamer

Substances

  • Acyclic Monoterpenes
  • Micelles
  • Poloxamer
  • citral